Lakefront Biotherapeutics (GLPGF) EPS (Diluted) Growth (3y) (2017 - 2026)
Powered by 
Analysis
Lakefront Biotherapeutics (GLPGF) EPS (Diluted) Growth (3y) (2017 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.50 Bn | 197.51 Bn | 7.24 Bn | 19.35% |
| 2 | Gilead Sciences | 181.29 Bn | 178.11 Bn | 6.22 Bn | -130.36% |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 7.01% |
| 4 | Regeneron Pharmaceuticals | 82.55 Bn | 74.56 Bn | 3.93 Bn | 12.90% |
| 5 | Argenx Se | 61.65 Bn | 56.47 Bn | 1.37 Bn | 82.91% |
| 6 | Moderna | 54.65 Bn | 49.52 Bn | 52.00 Mn | 18.44% |
| 7 | Alnylam Pharmaceuticals | 34.18 Bn | 30.87 Bn | 992.69 Mn | 36.39% |
| 8 | Biogen | 31.36 Bn | 30.07 Bn | 1.96 Bn | -45.62% |
| 9 | Roivant Sciences | 30.01 Bn | 30.01 Bn | 1.16 Mn | - |
| 10 | Lakefront Biotherapeutics | 1.73 Bn | 1.73 Bn | 3.51 Mn | -332.82% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -332.82% |
| Mar 31, 2026 | -12.10% |
| Dec 31, 2025 | 1,069.07% |
| Sep 30, 2025 | -281.30% |
| Jun 30, 2025 | 168.19% |
| Mar 31, 2025 | -178.19% |
| Dec 31, 2024 | 1,258.90% |
| Sep 30, 2024 | 15.59% |
| Jun 30, 2024 | 40.23% |
| Mar 31, 2024 | 104.57% |
| Dec 31, 2023 | 929.57% |
| Sep 30, 2023 | 44.61% |
| Jun 30, 2023 | 26.09% |
| Mar 31, 2023 | 34.04% |
| Dec 31, 2022 | 54.26% |
| Sep 30, 2022 | -72.21% |
| Jun 30, 2022 | 46.66% |
| Mar 31, 2022 | 52.50% |
| Dec 31, 2021 | -51.27% |
| Sep 30, 2021 | -113.22% |